Lundbeck sells off flopped Alzheimer's drug as Aduhelm approval ups interest

Taking a cue from the many Big Pharmas rushing to revive failed or mediocre Alzheimer's disease drugs, China’s Denovo Biopharma has picked up a discarded candidate from Lundbeck.

Lundbeck has offloaded the rights to a 5-HT6 receptor antagonist that failed three phase 3 clinical trials in 2016 and 2017. Denovo has claimed the global rights, but Lundbeck will retain an option to reacquire the asset down the line.